Synaffix

Developer of an antibody conjugation technology platform designed to help in the treatment of targeted cancer and other diseases. The company's technology utilizes an enzymatic modification of the naturally occurring glycan anchor points that exist on all antibodies to facilitate efficient, site-specific, and stable conjugation of potent anti-cancer molecules using extensively optimized metal-free click chemistry, thereby enabling clinicians to design complex biological drugs without the need for prior genetic modifications.

Partnerships